Cellink

The world has a shortage of organs suitable for human transplantation. In the US alone, as of March 2020 there were over 112,000 men, women, and children on the national transplant waiting list.
What if scientists could 3D-print new organs with a patients' own cells, eliminating the need for donated organs and the risk of rejection when organs are transplanted? That's exactly the path Cellink is pursuing: producing bioink and bioprinting technologies to enable researchers to 3D-print organs and tissue for applications that span industries, from pharmaceutical to cosmetic. 

In 2016, CELLINK commercialized the world’s first bioink, a biomaterial innovation eight years in the making. That milestone was the first of many along the company’s journey to become the world’s leading bioprinting company; they currently have systems to optimize cell-based applications for more than 1,000 scientists across more than 55 countries.

CELLINK was the first company to provide a standardized bio-ink product for sale over the internet. Researchers leverage its technologies to print liver, cartilage, skin tissues and more.

Cellink contributes to the UN Sustainable Development Goal 3: Good Health and Well-Being by driving innovations that ensure healthy lives and promote well-being for people of all ages. The company develops cutting-edge bioink and bioprinting technologies that bring scientists closer to the possibility of 3D-printing organs using a patient’s own cells—reducing dependence on organ donation and eliminating the risk of rejection. Through these advances, Cellink is helping to transform the future of regenerative medicine and patient care.

The 3DEXPEIENCE platform enables Cellink to better predict and understand how living material will behave once it is bioprinted. The team can identify problems and virtually develop fixes before bioprinting an actual structure. By optimizing this process, Cellink can help academia and pharmaceutical companies efficiently bioprint organs and to test drugs in a unique, organ-like environment to accelerate research.